Contrast Induced Acute Kidney in Patients With Acute Stroke

Stroke, Acute Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03132558
• Other study ID #: AISAKI001
• Status: Recruiting
• Phase: N/A
• First received: April 25, 2017
• Last updated: November 4, 2017
• Start date: September 2016
• Est. completion date: December 2017

Study information

• Verified date: November 2017
• Source: Nanjing Medical University
• Contact: HaiBin Shi, MD.
• Email: shihb[@]njmu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Computed tomographic angiography (CTA) is recommended for identifying eligible patient with acute ischemic stroke (AIS) to receieve endovascular treatment. We are going to conduct this prospective corhot study to observe if sequential use contrast in CTA examination and in endovascular treatment will cause acute kidney injury.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2017
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients who are suspected with AIS.

• Non-contrast head CT excludes intracranial hemorrhage.

Exclusion Criteria:

• Lacking of pre-CTA Creatinine

• Lacking of post-angiography Creatinine with 24-48 hours

Related Conditions & MeSH terms

• Stroke
• Stroke, Acute

Intervention

Drug:
• Radiopaque Media

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Nanjing Medical University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Creatinine	Contrast-induced acute kidney injury was defined as a relative increase of 25% or an absolute increase of 0.3 mg/dL (28.2mol/L) in the serum creatinine level at 48 hours following angiography	within 24h to 48h